Rock Springs Capital
Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to
Business Model: B2B
Revenue: $9.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Rock Springs Capital Information
Geographic Data
Address: 650 S Exeter St
City: Baltimore
State: MD
Zip: 21202
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$823M
Social
Crunchbase
Metrics
5,414,657Website Global Rank
1,710Website Monthly Traffic
Twitter Followers
Description
Rock Springs Capital is an investment company located in Baltimore, Maryland. Its advisory activities include management services to security portfolios and portfolio management for businesses or institutional clients.
Contact Phone:
+14102200129
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 5/2014 | Spark Therapeutics | Series B | 72.8M |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2019 | Imperative Care | Series C | 0 |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 4/2015 | Mirna Therapeutics | Series D | 0 |
| 12/2018 | Vedanta Biosciences | Series C | 0 |
| 10/2021 | Patina | Series A | 50M |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
| 2/2021 | Xilio Therapeutics | Series C | 95M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 5/2020 | Pulmonx | Equity | 66M |
| 7/2021 | dMed | Series C | 0 |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 10/2020 | Honor | Series D | 140M |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 9/2015 | Corvus Pharmaceuticals | Series B | 75M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 5/2021 | Caris Life Sciences | Private Equity Round | 0 |
| 4/2019 | Inozyme | Series A | 67.4M |
| 2/2015 | Chiasma | Series E | 70M |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 1/2018 | Braeburn | Debt Financing | 0 |
| 12/2014 | Sagimet Biosciences | Series D | 28.5M |
| 8/2020 | Freenome | Series C | 270M |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 10/2022 | Treeline Biosciences | Series A | 261.3M |
| 12/2021 | Freenome | Series D | 300M |
| 12/2017 | Allakos | Series B | 100M |
| 1/2022 | Simcha Therapeutics | Series B | 40M |
| 6/2020 | Everest Medicines | Series C | 310M |
| 2/2023 | Spruce Biosciences | Post-IPO Equity | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 6/2015 | Clementia Pharmaceuticals | Venture Round | 0 |
| 7/2015 | Translate Bio | Series B | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 6/2015 | Advanced Accelerator Applications | Venture Round | 25.7M |
| 1/2021 | Affinivax | Series C | 226M |
| 2/2022 | MiRXES | Series C | 0 |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 6/2021 | Apollo Therapeutics | Venture Round | 139.4M |
| 8/2022 | Kymera Therapeutics | Post-IPO Equity | 150M |
| 6/2016 | Vedanta Biosciences | Private Equity Round | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 2/2023 | Hemab | Series B | 0 |
| 7/2020 | Kindbody | Series B | 0 |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 9/2015 | AveXis | Series D | 65M |
| 3/2019 | Imara | Series B | 0 |
| 11/2020 | Acumen Pharmaceuticals | Series B | 0 |
| 5/2020 | Atea | Series D | 215M |
| 11/2017 | resTORbio | Series A | 40M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 2/2021 | Sagimet Biosciences | Venture Round | 0 |
| 10/2014 | Invitae | Series F | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 11/2014 | Nivalis Therapeutics | Venture Round | 30M |
| 2/2021 | Personal Genome Diagnostics | Series C | 0 |
| 8/2014 | Dermira | Series C | 51M |
| 3/2015 | Mersana Therapeutics | Series B | 35M |
| 11/2018 | Aprea | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 12/2020 | Genesis Therapeutics | Series A | 52M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 3/2020 | Immunocore | Series B | 0 |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2015 | Adaptive Biotechnologies | Series F | 195M |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 6/2017 | Zai Lab | Series C | 30M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 11/2013 | TriVascular | Series E | 0 |
| 4/2014 | Adverum Biotechnologies | Series B | 55M |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 11/2015 | ObsEva | Series B | 58.9M |
| 4/2018 | Innovent Biologics | Series E | 150M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 6/2021 | Synthekine | Series B | 0 |
| 7/2020 | New Horizon Health | Series E | 30M |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 7/2021 | Clinipace | Venture Round | 0 |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 5/2017 | Synlogic | Series C | 42M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 6/2018 | Kaleido | Series C | 101M |
| 7/2021 | Vedanta Biosciences | Series D | 0 |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 7/2021 | MiRXES | Series C | 0 |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 7/2021 | Imperative Care | Series D | 0 |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 10/2021 | Honor | Series E | 70M |
| 5/2015 | BeiGene | Series B | 97M |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 7/2022 | Immunocore | Post-IPO Equity | 0 |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 2/2022 | MiRXES | Series C | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 0 |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 12/2021 | Freenome | Series D | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
